{"nctId":"NCT03506815","briefTitle":"Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines","startDateStruct":{"date":"2019-03-15","type":"ACTUAL"},"conditions":["Upper Extremity Deep Vein Thrombosis","Central Venous Catheter Thrombosis","Cancer"],"count":105,"armGroups":[{"label":"Rivaroxaban Thromboprophylaxis","type":"EXPERIMENTAL","interventionNames":["Drug: Rivaroxaban 10 MG"]},{"label":"Standard of care","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Rivaroxaban 10 MG","otherNames":["Xarelto 10mg tablet po daily"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1.Patients 18 years of age or older with a new or existing diagnosis of cancer with a CVC inserted within the last 72 hours.\n\nExclusion Criteria:\n\n1. CVC in place for \\>72 hours\n2. Patient requires anticoagulation for other indication\n3. Concomitant use of dual antiplatelet therapy\n4. Prior VTE\n5. Major bleeding event in the last 6 weeks\n6. Patient on concomitant medication with known interaction with rivaroxaban (eg. CYP3A4 inhibitor)\n7. Pregnancy (documentation of use of effective contraception if sexually active or negative B-Hcg required)\n8. Known renal failure, based on Creatinine clearance \\<30 mL/min (Cockcroft-Gault) (in the previous 3 months)\n9. Documented severe liver disease (eg. acute clinical hepatitis, chronic active hepatitis, cirrhosis or ALT \\>3ULN) ( in the previous 3 months)\n10. Known thrombocytopenia \\< 50x 109/L (in the previous 3 months)\n11. Allergy to rivaroxaban\n12. Life expectancy \\<6 months\n13. History of condition at increased bleeding risk including, but not limited to:\n\n    1. Major surgical procedure or trauma within 30 days before the randomization visit\n    2. Clinically significant gastrointestinal bleeding within 6 months before the randomization visit\n    3. History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding\n    4. Chronic hemorrhagic disorder\n    5. Known intracranial neoplasm, arteriovenous malformation, or aneurysm\n    6. Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg\n14. Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin or acute leukemia or myelodysplastic syndrome\n15. Geographic inaccessibility\n16. Refused or unable to obtain consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Feasibility Outcome - Number of Participants Recruited Per Month","description":"A convenience sample size of 100 patients was chosen to allow reporting of the average monthly recruitment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Feasibility Outcomes - Percentage of Participants With Good Adherence to Therapy","description":"Good adherence defined as 80% or greater study medication taken in patients randomized to receive Rivaroxaban thromboprophylaxis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Thrombotic Complication","description":"Thrombotic complication was defined as a combination of major venous thromboembolism (VTE); any symptomatic or incidentally detected proximal deep vein thrombosis (DVT) of the lower or upper limbs, any nonfatal symptomatic or incidental pulmonary embolism (PE), and pulmonary embolism-related death) and any other deep (ie, distal, splanchnic, or cerebral) or superficial venous thrombosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With CVC-Related Complication","description":"Central venous catheter (CVC) occlusion was defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood, and/or administer solutions or medications","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Major Bleeding","description":"Defined by the International Society on Thrombosis and Haemostasis (ISTH) as overt bleeding associated with a decrease in the hemoglobin level of ≥2 g/dL, which led to transfusion of two or more units of packed red blood cells, occurred in a critical site, or contributed to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Clinically Relevant Non-Major Bleed","description":"Clinically relevant non-major bleeding, as per the standardized definition by the ISTH, is any signs or symptoms of hemorrhage not meeting criteria for major bleeding but associated with medical intervention, unscheduled in-person contact with a healthcare professional or need for hospitalization or increased level of care.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":52},"commonTop":["Thrombocytopenia","Fever","Rash","Anemia","Chemotherapy Infusion Reaction"]}}}